Elicio Therapeutics, Inc.
ELTXNasdaqCIK 1601485HealthcareFiscal year ends Dec 31
Reports and events: 130 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0920:05 ET | DEF 14A | Proxy statementPeriod 2025-12-31 | 0001601485-26-000061 |
| 2026-09-1420:03 ET | 8-K | 5.08 Item not in the standard list; 8.01 Other events | 0001601485-26-000058 |
| 2026-08-1320:08 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001601485-26-000056 |
| 2026-08-1320:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001601485-26-000055 |
| 2026-07-0210:20 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-080058 |
| 2026-06-2420:05 ET | 8-K | 7.01 Regulation FD disclosure | 0001601485-26-000050 |
| 2026-06-1712:03 ET | 8-K | 8.01 Other events | 0001601485-26-000048 |
| 2026-06-1513:21 ET | 8-K | 8.01 Other events | 0001601485-26-000046 |
| 2026-05-1120:12 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001601485-26-000042 |
| 2026-05-1120:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001601485-26-000041 |
| 2026-04-2920:06 ET | 10-K/A | Annual report, amendedPeriod 2025-12-31 | 0001601485-26-000035 |
| 2026-03-1613:19 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement | 0001601485-26-000032 |
| 2026-03-1220:24 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001601485-26-000027 |
| 2026-03-1220:08 ET | 8-K | 2.02 Results of operations | 0001601485-26-000026 |
| 2025-11-1321:08 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001601485-25-000124 |
| 2025-11-1321:04 ET | 8-K | 2.02 Results of operations | 0001601485-25-000123 |
| 2025-09-1712:16 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-205522 |
| 2025-08-1212:01 ET | 8-K | 8.01 Other events | 0001601485-25-000114 |
| 2025-08-0720:49 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001601485-25-000111 |
| 2025-08-0720:33 ET | 8-K | 2.02 Results of operations | 0001601485-25-000108 |
| 2025-08-0511:08 ET | 8-K | 8.01 Other events | 0001601485-25-000099 |
| 2025-06-0421:06 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000950170-25-081739 |
| 2025-06-0412:03 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001601485-25-000096 |
| 2025-05-2012:06 ET | 8-K | 5.07 Shareholder vote results | 0001601485-25-000076 |
| 2025-05-1320:31 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001601485-25-000074 |
| 2025-05-1320:27 ET | 8-K | 2.02 Results of operations | 0001601485-25-000072 |
| 2025-04-0920:18 ET | DEF 14A | Proxy statementPeriod 2025-04-09 | 0001601485-25-000062 |
| 2025-03-3111:07 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001601485-25-000049 |
| 2025-03-3111:01 ET | 8-K | 2.02 Results of operations | 0001601485-25-000046 |
| 2025-03-2411:03 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001601485-25-000022 |
| 2025-03-0721:07 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000950170-25-035497 |
| 2025-03-0521:05 ET | 8-K | 3.02 Unregistered sale of equity | 0001601485-25-000018 |
| 2025-01-3014:03 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-016455 |
| 2025-01-2321:36 ET | 8-K | 7.01 Regulation FD disclosure | 0001601485-25-000009 |
| 2025-01-2212:33 ET | 8-K | 8.01 Other events | 0001601485-25-000006 |
| 2024-12-1212:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events | 0001601485-24-000107 |
| 2024-12-0312:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-269400 |
| 2024-11-2121:06 ET | 8-K | 5.07 Shareholder vote results | 0001601485-24-000083 |
| 2024-11-1321:11 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001601485-24-000075 |
| 2024-11-1321:10 ET | 8-K | 2.02 Results of operations | 0001601485-24-000074 |
| 2024-11-0721:27 ET | 8-K | 8.01 Other events | 0001601485-24-000067 |
| 2024-11-0714:30 ET | 8-K | 8.01 Other events | 0001601485-24-000063 |
| 2024-10-1712:31 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001601485-24-000057 |
| 2024-09-2720:41 ET | DEF 14A | Proxy statementPeriod 2024-11-07 | 0001140361-24-042209 |
| 2024-08-3012:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001140361-24-039592 |
| 2024-08-1421:01 ET | SC 13D/A | Ownership report, active investor, amended | 0001068238-24-000167 |
| 2024-08-1320:58 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001601485-24-000045 |
| 2024-08-1320:33 ET | 8-K | 2.02 Results of operations | 0001601485-24-000042 |
| 2024-08-1220:24 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-24-036848 |
| 2024-07-0220:39 ET | SC 13D/A | Ownership report, active investor, amended | 0001068238-24-000141 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.